4.1 Article

Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study

期刊

INTERNATIONAL JOURNAL OF HEMATOLOGY
卷 112, 期 6, 页码 787-794

出版社

SPRINGER JAPAN KK
DOI: 10.1007/s12185-020-02971-1

关键词

Aplastic anemia; Romiplostim; Eltrombopag; Thrombopoietin receptor-agonists

资金

  1. Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development, AMED [19ck0106251h0003]

向作者/读者索取更多资源

Eltrombopag (EPAG) and romiplostim (ROM), thrombopoietin receptor-agonists with demonstrated efficacy against aplastic anemia (AA) in prospective controlled studies, were authorized in Japan for use in adults with aplastic anemia in 2017 and 2019, respectively. So far, no data are available on the potential contribution of switching from ROM to EPAG or vice versa in terms of efficacy or tolerance. Efficacies and tolerance profiles of ten patients, who failed to respond to the maximum dose of EPAG and then switched to ROM, were evaluated. All ten patients received a maximum dose of ROM (20 mu g/kg/week). At a median follow-up of twelve months, seven of ten patients (70%) had achieved either neutrophil, erythroid, or platelet response, including one complete response. No patients showed platelet count fluctuations that were reported during ROM treatment for immune thrombocytopenia. In univariate analysis of the relationship between efficacy and demographics, the response had a correlation with neither factors. None of the patients stopped the ROM treatment because of adverse events. Although a larger number of patients and a longer follow-up period are needed to confirm our findings, our results show the efficacy of ROM in patients with EPAG-refractory AA.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据